Pharmaceutical formulation
AssigneeAbbott Laboratories
InventorsFortuna Haviv, Bryan K. Erickson, Jack Henkin, Luk C. Li, Fanfeng Ma, Friedrich W. Richter, Yi Shi, Jingfeng Song, Siriporn Toongsuwan
Life of this patent
Estimating the term…
Abstract
Parenteral formulations of peptides which are useful for sustained release are disclosed. Also disclosed are methods of preparation for the formulations.
Claims53
A pharmaceutical composition comprising:
- (a) a therapeutically effective amount of a compound of formula (I) R1-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Ile-Arg-Pro-Xaa10 (I), (SEQ ID NO:1);
- or a therapeutically acceptable salt thereof, wherein
- R1 is CH3—C(O)—;
- Xaa1 is absent or sarcosyl;
- Xaa2 is absent or glycyl;
- Xaa3 is absent or selected from the group consisting of glutaminyl and valyl;
- Xaa4 is absent or selected from the group consisting of D-alloisoleucyl and D-isoleucyl;
- Xaa5 is selected from the group consisting of seryl and threonyl;
- Xaa6 is selected from the group consisting of glutaminyl, norvalyl, and seryl;
- and
- xaa10 is selected from the group consisting of —NHCH2CH3 and D-alanylethylamide;
- provided that when Xaa4 is D-alloisoleucyl, Xaa1 is absent;
- (b) poly(lactide-co-glycolide);
- and
- (c) an organic solvent.
A pharmaceutical composition comprising:
- (a) about 3% to about 5% (w/w) of the compound of formula (Ia) N-Ac-Sar-Gly-Val-DIle-Thr-Nva-Ile-Arg-ProNHCH2CH3 (Ia), or a therapeutically acceptable salt thereof;
- (b) about 35% (w/w) poly(lactide-co-glycolide);
- and
- (c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.
A pharmaceutical composition comprising:
- (a) about 3% (w/w) of the compound of formula (Ib) N-Ac-Sar-Gly-Val-DIle-Thr-Gln-Ile-Arg-ProNHCH2CH3 (Ib), or a therapeutically acceptable salt thereof;
- (b) about 35% (w/w) poly(lactide-co-glycolide);
- and
- (c) about a 1:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.
A pharmaceutical composition comprising:
- (a) about 6% (w/w) of the compound of formula (Ib) N-Ac-Sar-Gly-Val-DIle-Thr-Gln-Ile-Arg-ProNHCH2CH3 (Ib), or a therapeutically acceptable salt thereof;
- (b) about 33% (w/w) poly(lactide-co-glycolide);
- and
- (c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.
A pharmaceutical composition comprising:
- (a) about 3% (w/w) of the compound of formula (Ic) N-Ac-DalloIle-Ser-Ser-Ile-Arg-ProNHCH2CH3 (Ic), or a therapeutically acceptable salt thereof;
- (b) about 34% (w/w) poly(lactide-co-glycolide);
- and
- (c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.
A pharmaceutical composition comprising:
- (a) about 3% (w/w) of the compound of formula (Id) N-Ac-Gly-Val-DalloIle-Ser-Gln-Ile-Arg-ProNHCH2CH3 (Id), or a therapeutically acceptable salt thereof;
- (b) about 34% (w/w) poly(lactide-co-glycolide);
- and
- (c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.
A method for preparing a pharmaceutical composition comprising:
- (a) combining between about 25% and about 45% (w/w) poly(lactide-co-glycolide) and about 1% to about 15% (w/w) of a compound of formula (I), or a therapeutically acceptable salt thereof, in an organic solvent;
- and
- (b) stirring the product of step (a).
A method for preparing a pharmaceutical composition comprising:
- (a) dissolving between about 25% and about 45% (w/w) poly(lactide-co-glycolide) in an organic solvent selected from the group consisting of N-methyl-2-pyrrolidinone, triacetin, 2-pyrrolidinone, and mixtures thereof;
- (b) treating the product of step (a) with about 2% to about 10% (w/w) of a compound of formula (I), or a therapeutically acceptable salt thereof;
- and
- (c) stirring the product of step (b).
A method for preparing a pharmaceutical composition comprising:
- (a) dissolving about 35% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
- (b) treating the product of step (a) with about 3% to about 5% (w/w) of the compound of formula (Ia), or a therapeutically acceptable salt thereof;
- and
- (c) stirring the product of step (b) at about 20° C. to about 25° C.
A method for preparing a pharmaceutical composition comprising:
- (a) dissolving about 35% (w/w) 13 KD poly(lactide-co-glycolide) in about a 1:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
- (b) treating the product of step (a) with about 3% (w/w) of the compound of formula (Ib), or a therapeutically acceptable salt thereof;
- and
- (c) stirring the product of step (b) at about 20° C. to about 25° C.
A method for preparing a pharmaceutical composition comprising:
- (a) dissolving about 33% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
- (b) treating the product of step (a) with about 6% (w/w) of the compound of formula (Ib), or a therapeutically acceptable salt thereof;
- and
- (c) stirring the product of step (b) at about 20° C. to about 25° C.
A method for preparing a pharmaceutical composition comprising:
- (a) dissolving about 34% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
- (b) treating the product of step (a) with about 3% (w/w) of the compound of formula (Ic), or a therapeutically acceptable salt thereof;
- and
- (c) stirring the product of step (b) at about 20° C. to about 25° C.
A method for preparing a pharmaceutical composition comprising:
- (a) dissolving about 34% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
- (b) treating the product of step (a) with about 3% (w/w) of the compound of formula (Id), or a therapeutically acceptable salt thereof;
- and
- (c) stirring the product of step (b) at about 20° C. to about 25° C.
A method for providing sustained delivery of a peptide comprising administering to a subject a pharmaceutical composition comprising:
- (a) about 1% to about 15% (w/w) of a compound of formula (I) R1-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Ile-Arg-Pro-Xaa10 (I), (SEQ ID NO:1);
- or a therapeutically acceptable salt thereof, wherein
- R1 is CH3—C(O)—;
- Xaa1 is absent or sarcosyl;
- Xaa2 is absent or glycyl;
- Xaa3 is absent or selected from the group consisting of glutaminyl and valyl;
- Xaa4 is absent or selected from the group consisting of D-alloisoleucyl and D-isoleucyl;
- Xaa5 is selected from the group consisting of seryl and threonyl;
- Xaa6 is selected from the group consisting of glutaminyl, norvalyl, and seryl;
- and
- Xaa10 is selected from the group consisting of —NHCH2CH3 and D-alanylethylamide;
- provided that when Xaa4 is D-alloisoleucyl, Xaa1 is absent;
- (b) about 25% to about 45% (w/w) poly(lactide-co-glycolide);
- and
- (c) an organic solvent selected from the group consisting of N-methyl-2-pyrrolidinone, triacetin, and mixtures thereof.
Dependencies are inferred from the claim text.